Oral Complement Factor D Inhibitor for Breakthrough Hemolysis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), often require life-long intravenous injections and do not adequately control breakthrough hemolysis due to variable pharmacokinetic and pharmacodynamic profiles.
Innovation Solution
Development of an oral dosage form of the small molecule complement factor D (fD) inhibitor (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide, which maintains effective plasma concentrations and inhibits the alternative complement pathway with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If life-long intravenous injections of eculizumab are administered, then complement-mediated disorders are treated, but patient convenience deteriorates and treatment compliance becomes difficult
Solution Approach 1:
The patent replaces the mechanical intravenous injection system with an oral dosage form. The small molecule complement factor D inhibitor is administered orally as a pill or tablet, eliminating the need for intravenous access, infusion pumps, and clinical setting requirements, while maintaining therapeutic effectiveness through oral bioavailability
Solution Approach 2:
The patent introduces an oral bioavailable formulation as an intermediary between the active drug molecule and the patient's systemic circulation. The dosage form includes excipients and delivery mechanisms that enable the drug to survive gastric conditions, dissolve appropriately, and achieve sufficient plasma concentrations without intravenous administration
2Ease of operation
If standard dosing regimens are used, then treatment is simplified, but breakthrough hemolysis control deteriorates due to variable pharmacokinetic profiles
Solution Approach 1:
The patent implements dynamic dosing regimens that adjust timing and potentially dosage based on individual patient pharmacokinetic profiles, metabolic rate variations, and disease activity. The system monitors plasma concentrations and clinical markers to optimize dosing intervals, ensuring Ctrough levels remain above the EC90 threshold while preventing breakthrough hemolysis
Solution Approach 2:
The patent incorporates feedback mechanisms where patient responses, plasma drug concentrations, and hemolysis markers are monitored to adjust subsequent dosing decisions. This closed-loop approach ensures that dosing regimens are continuously optimized to maintain effective inhibitor levels while preventing breakthrough events
3Reliability
If high plasma concentrations are maintained to prevent breakthrough hemolysis, then complement pathway inhibition is improved, but side effects increase
Solution Approach 1:
The patent optimizes the drug molecule's pharmacokinetic parameters including half-life, bioavailability, and clearance rate through structural modifications and formulation approaches. By changing these parameters, the drug achieves sustained effective concentrations with less frequent dosing and lower peak concentrations, reducing the risk of concentration-dependent side effects while maintaining reliable complement pathway inhibition
Data Source
AI summary
The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Ctrough at least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low Cmax, providing additional safety margin and better dosing flexibility.